Two centuries. Countless innovations. One vision.
Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
Takeda to Hold Oncology Focused Investor Call on June 8
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
SEE ALL NEWS AND RELEASES >
・For Shire news releases, click here
Luck is not a strategy: The world needs to start preparing now for the next pandemic
The COVID-19 Mental Burden on Working Mothers
Takeda Neuroscience at the Annual Meeting of the American Academy of Neurology (AAN) 2021
Takeda Breaks Ground on Commercial Cell Therapy Manufacturing Facility in Lexington, Massachusetts
Spotlight Malawi: Many Paths Towards Universal Health Coverage and a Strong Health Workforce
SEE ALL FEATURED TOPICS ARTICLES >
With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Copyright 1995-2021 Takeda Pharmaceutical Company Limited. All rights reserved.